Design Therapeutics, Inc. Operating Expenses
Design Therapeutics, Inc. (DSGN) reported Operating Expenses of $22.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-03
- Design Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $22.18M, a 2.82% increase year-over-year.
- Design Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $19.71M, a 3.49% decline year-over-year.
- Design Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $18.17M, a 8.84% increase year-over-year.
- Design Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $19.31M, a 18.87% increase year-over-year.
- Design Therapeutics, Inc. operating expenses for fiscal 2025 was $79.47M, a 27.39% increase from fiscal 2024.
- Design Therapeutics, Inc. operating expenses for fiscal 2024 was $62.38M, a 20.22% decline from fiscal 2023.
- Design Therapeutics, Inc. operating expenses for fiscal 2023 was $78.19M, a 15.68% increase from fiscal 2022.
- Design Therapeutics, Inc. operating expenses for fiscal 2022 was $67.59M, a 88.64% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.18M 10-Q · filed 2026-08-03 | $41.88M 10-Q · filed 2026-08-03 | $60.05M derived: sum of 3 quarters · filed 2026-08-03 | $79.36M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $19.71M 10-Q · filed 2026-04-28 | $37.88M derived: sum of 2 quarters · filed 2026-04-28 | $57.19M derived: sum of 3 quarters · filed 2026-04-28 | $78.75M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $18.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $37.48M derived: sum of 2 quarters · filed 2026-03-09 | $59.05M derived: sum of 3 quarters · filed 2026-08-03 | $79.47M 10-K · filed 2026-03-09 |
| 2025-09-30 | $19.31M 10-Q · filed 2025-11-05 | $40.88M derived: sum of 2 quarters · filed 2026-08-03 | $61.30M 10-Q · filed 2025-11-05 | $77.99M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $21.57M 10-Q · filed 2026-08-03 | $41.99M 10-Q · filed 2026-08-03 | $58.68M derived: sum of 3 quarters · filed 2026-08-03 | $74.93M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $20.42M 10-Q · filed 2026-04-28 | $37.11M derived: sum of 2 quarters · filed 2026-04-28 | $53.36M derived: sum of 3 quarters · filed 2026-04-28 | $68.40M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $16.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $32.94M derived: sum of 2 quarters · filed 2026-03-09 | $47.98M derived: sum of 3 quarters · filed 2026-03-09 | $62.38M 10-K · filed 2026-03-09 |
| 2024-09-30 | $16.25M 10-Q · filed 2025-11-05 | $31.29M derived: sum of 2 quarters · filed 2025-11-05 | $45.69M 10-Q · filed 2025-11-05 | $60.81M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $15.04M 10-Q · filed 2025-08-07 | $29.44M 10-Q · filed 2025-08-07 | $44.56M derived: sum of 3 quarters · filed 2025-08-07 | $63.39M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $14.40M 10-Q · filed 2025-05-07 | $29.52M derived: sum of 2 quarters · filed 2025-05-07 | $48.34M derived: sum of 3 quarters · filed 2025-05-07 | $70.94M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $15.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $33.94M derived: sum of 2 quarters · filed 2025-03-10 | $56.54M derived: sum of 3 quarters · filed 2025-03-10 | $78.19M 10-K · filed 2025-03-10 |
| 2023-09-30 | $18.82M 10-Q · filed 2024-11-07 | $41.42M derived: sum of 2 quarters · filed 2024-11-07 | $63.07M 10-Q · filed 2024-11-07 | $82.46M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $22.60M 10-Q · filed 2024-08-05 | $44.25M 10-Q · filed 2024-08-05 | $63.64M derived: sum of 3 quarters · filed 2024-08-05 | $82.83M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $21.65M 10-Q · filed 2024-05-08 | $41.04M derived: sum of 2 quarters · filed 2024-05-08 | $60.23M derived: sum of 3 quarters · filed 2024-05-08 | $75.87M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $38.58M derived: sum of 2 quarters · filed 2024-03-19 | $54.22M derived: sum of 3 quarters · filed 2024-03-19 | $67.59M 10-K · filed 2024-03-19 |
| 2022-09-30 | $19.19M 10-Q · filed 2023-11-13 | $34.83M derived: sum of 2 quarters · filed 2023-11-13 | $48.20M 10-Q · filed 2023-11-13 | $59.33M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $15.64M 10-Q · filed 2023-08-14 | $29.01M 10-Q · filed 2023-08-14 | $40.14M derived: sum of 3 quarters · filed 2023-08-14 | $51.47M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $13.37M 10-Q · filed 2023-05-09 | $24.50M derived: sum of 2 quarters · filed 2023-05-09 | $35.83M derived: sum of 3 quarters · filed 2023-05-09 | $43.52M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $11.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $22.46M derived: sum of 2 quarters · filed 2023-03-14 | $30.15M derived: sum of 3 quarters · filed 2023-03-14 | $35.83M 10-K · filed 2023-03-14 |
| 2021-09-30 | $11.34M 10-Q · filed 2022-11-03 | $19.02M derived: sum of 2 quarters · filed 2022-11-03 | $24.70M 10-Q · filed 2022-11-03 | $28.60M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $7.69M 10-Q · filed 2022-08-08 | $13.37M 10-Q · filed 2022-08-08 | $17.26M derived: sum of 3 quarters · filed 2022-08-08 | $19.66M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $5.68M 10-Q · filed 2022-05-09 | $9.57M derived: sum of 2 quarters · filed 2022-05-09 | $11.98M derived: sum of 3 quarters · filed 2022-05-09 | $13.47M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $6.30M derived: sum of 2 quarters · filed 2022-03-10 | $7.79M derived: sum of 3 quarters · filed 2022-03-10 | $8.56M 10-K · filed 2022-03-10 |
| 2020-09-30 | $2.40M 10-Q · filed 2021-11-09 | $3.90M derived: sum of 2 quarters · filed 2021-11-09 | $4.66M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $1.49M 10-Q · filed 2021-08-09 | $2.26M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $765.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |